Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) EBIT Margin (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of EBIT Margin readings, the most recent being 225.0% for Q1 2025.

  • Quarterly EBIT Margin changed N/A to 225.0% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 790.9% through Dec 2025, changed N/A year-over-year, with the annual reading at 790.9% for FY2025, N/A changed from the prior year.
  • EBIT Margin hit 225.0% in Q1 2025 for Oramed Pharmaceuticals, up from 562.46% in the prior quarter.
  • Across five years, EBIT Margin topped out at 225.0% in Q1 2025 and bottomed at 1693.92% in Q2 2022.
  • Average EBIT Margin over 4 years is 1051.65%, with a median of 1048.44% recorded in 2021.
  • Peak annual rise in EBIT Margin hit 113145bps in 2023, while the deepest fall reached 90751bps in 2023.
  • Oramed Pharmaceuticals' EBIT Margin stood at 896.15% in 2021, then plummeted by -52bps to 1363.5% in 2022, then skyrocketed by 59bps to 562.46% in 2023, then skyrocketed by 60bps to 225.0% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBIT Margin are 225.0% (Q1 2025), 562.46% (Q2 2023), and 781.98% (Q1 2023).